Regeneron

6,141

$617.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.98 (-0.80%) Today
+$1.22 (+0.20%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Employees
8,100
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
69.30B
Price-Earnings Ratio
31.20
Dividend Yield
Average Volume
1.09M
High Today
$633.84
Low Today
$614.37
Open Price
$623.67
Volume
733.43K
52 Week High
$655.93
52 Week Low
$271.37

Collections

REGN News

BenzingaJul 11

Barron's Picks And Pans: Facebook, Nokia, Regeneron And More

This weekend's Barron's cover story presents the results from the Barron's 2020 Midyear Roundtable. Other featured articles look how to manage risk in a time o
0
New York TimesJul 9

These Scientists Raced to Find a Covid-19 Drug. Then the Virus Found Them.

If the trials are successful, company executives have said the treatment could be available by the end of the summer. The hope is that it could serve as a stopg
0
MarketWatchJul 9

Regeneron shares are up 2% after SunTrust upgrades the stock

Shares of Regeneron Pharmaceuticals Inc. REGN, +1.57% were up 2.1% in trading on Thursday as SunTrust Robinson Humphrey analysts upgraded the stock to buy from
0

REGN Earnings

$0.00
$2.50
$5.00
$7.50
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
per share
Actual
Available Aug 5, Pre-Market

You May Also Like

More REGN News

The EconomistJul 8

The Economist explains - Can antibody therapies control covid-19?

THIS WEEK an American pharmaceutical company, Regeneron, announced that it had a new drug for covid-19 entering late-stage clinical trials. This is one of sever
0
BenzingaJul 7

Why Regeneron's Stock Is Trading Higher Today

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher on Tuesday after the company announced it has been awarded a $450 million contract to manufac
0
CNBCJul 7

Regeneron signs a $450 million contract with the U.S. government for its coronavirus therapy

Regeneron Pharmaceuticals said on Tuesday the U.S. government signed a $450 million contract with the drugmaker to make and supply its potential double-antibody
0
CNBCJul 7

Stocks making the biggest moves in the premarket: Novavax, Regeneron, Square, Nvidia & more

Take a look at some of the biggest movers in the premarket: Novavax (NVAX) – Novavax was awarded $1.6 billion in funding from "Operation Warp Speed," the gover
0
ReutersJul 7

U.S. signs $450 million contract with Regeneron for COVID-19 therapy

(Reuters) - The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc (REGN.O) for its potential COVID-19 antibody cocktail, the dru
0
MarketWatchJul 7

Regeneron's stock gains on $450 million manufacturing deal with U.S. for experimental COVID-19 treatment

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.77% gained 0.9% in premarket trading on Tuesday after the drugmaker said it received $450 million from the fed
0
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.